An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus With Repeated Administration Courses in Patients With Clinical Benefit
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Bivatuzumab mertansine (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 07 Oct 2014 New trial record